Aqualung says Phase 2a trial validates eNAMPT target in ARDS

Aqualung Therapeutics said its Phase 2a PUERTA study of ALT-100 in moderate-to-severe ARDS showed early clinical and biomarker improvements with safety similar to placebo. The company says the peer-reviewed data are the first human validation of the eNAMPT pathway and could support expansion into other inflammatory and fibrotic diseases.

Why it matters: - Aqualung Therapeutics says the PUERTA Phase 2a data provide the first peer-reviewed clinical validation of the eNAMPT pathway in humans. - The findings could strengthen the case for ALT-100 as a platform therapy for acute respiratory distress syndrome and other inflammatory and fibrotic diseases. - ARDS has high mortality and no FDA-approved pharmacologic therapy.

What happened: - Aqualung Therapeutics announced publication of positive results from its randomized, double-blind, placebo-controlled PUERTA Phase 2a trial of ALT-100. - The study enrolled patients with moderate-to-severe acute respiratory distress syndrome. - The paper appeared in the American Journal of Respiratory and Critical Care Medicine. - The company said the publication covers the first 15 patients in the study.

The details: - ALT-100 showed improvements in Day 3 Sequential Organ Failure Assessment scores versus placebo. - The treatment was associated with more ventilator-free days. - ALT-100 reduced key inflammatory biomarkers, including IL-6, IL-1β and circulating eNAMPT. - The study showed a favorable safety profile. - Treatment-emergent adverse events and serious adverse events were comparable with placebo. - Aqualung said the results also support its eNamptor precision medicine platform, which pairs therapy with genomic and biomarker-based patient identification. - The company is developing ALT-100 as a first-in-class eNAMPT-neutralizing monoclonal antibody. - Aqualung is advancing ALT-100 for ARDS, pulmonary fibrosis and other diseases marked by dysregulated inflammation and fibrosis.

Between the lines: - The data give Aqualung an external, peer-reviewed readout for a target the company has been building its broader strategy around. - Positive biomarker movement matters because the company is positioning eNAMPT as a central regulator of inflammation and fibrosis, not just a single-disease target. - The trial signal is early, so the main question now is whether the biologic activity scales into larger studies and clearer clinical benefit.

What's next: - Aqualung said it is evaluating the best clinical development strategy for ALT-100 across inflammatory and fibrotic indications. - The company also plans to continue expanding the clinical utility of the eNamptor platform. - Aqualung said the ARDS results support further study in additional pulmonary and systemic inflammatory diseases, including progressive pulmonary fibrosis. - More information is available on the company's announcement at Aqualung Therapeutics.